Masahiko Mihara

Summary

Affiliation: Chugai Pharmaceutical Co
Country: Japan

Publications

  1. ncbi Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorates joint swelling in established monkey collagen-induced arthritis
    Yasushi Uchiyama
    Product Research Department, Chugai Pharmaceutical Co, Ltd, Gotemba, Shizuoka, Japan
    Biol Pharm Bull 31:1159-63. 2008
  2. ncbi Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family
    Masahiko Mihara
    Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co Ltd, 1 135, Komakado, Gotemba, Shizuoka, 412 8513, Japan
    Int Immunopharmacol 5:1731-40. 2005
  3. ncbi The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody
    Masahiko Mihara
    Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co Ltd, 135, Komakado 1 Chome, Shizuoka, 412 8513 Japan
    Expert Opin Biol Ther 5:683-90. 2005
  4. ncbi Evidence for the role of Th17 cell inhibition in the prevention of autoimmune diseases by anti-interluekin-6 receptor antibody
    Masahiko Mihara
    Product Research Department, Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co Ltd, Komakado 1 Chome, Gotemba shi, Shizuoka, Japan
    Biofactors 35:47-51. 2009
  5. ncbi Anti-interleukin 6 receptor antibody inhibits murine AA-amyloidosis
    Masahiko Mihara
    Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co Ltd, Shizuoka, Japan
    J Rheumatol 31:1132-8. 2004
  6. ncbi Influences of anti-mouse interleukin-6 receptor antibody on immune responses in mice
    Masahiko Mihara
    Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co Ltd, 135, Komakado 1 Chome, Gotemba shi, Shizuoka 412 8513, Japan
    Immunol Lett 84:223-9. 2002
  7. ncbi IL-6/IL-6 receptor system and its role in physiological and pathological conditions
    Masahiko Mihara
    Fuji Gotemba Research Laboratories, Product Research Department, Chugai Pharmaceutical Co Ltd, Gotemba, Japan
    Clin Sci (Lond) 122:143-59. 2012
  8. ncbi Different effects of high molecular weight sodium hyaluronate and NSAID on the progression of the cartilage degeneration in rabbit OA model
    M Mihara
    Product Research Department, Chugai Pharmaceutical Co, Ltd, Shizuoka, Japan
    Osteoarthritis Cartilage 15:543-9. 2007
  9. ncbi IL-6 and IL-1 synergistically enhanced the production of MMPs from synovial cells by up-regulating IL-6 production and IL-1 receptor I expression
    Miho Suzuki
    Product Research Department, Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co, Ltd, Shizuoka, Japan
    Cytokine 51:178-83. 2010
  10. ncbi Tocilizumab, a humanized anti-interleukin-6 receptor antibody, improved anemia in monkey arthritis by suppressing IL-6-induced hepcidin production
    Misato Hashizume
    Product Research Department, Chugai Pharmaceutical Co, Ltd, 1 135 Komakado, Gotemba, Shizuoka, 412 8513, Japan
    Rheumatol Int 30:917-23. 2010

Collaborators

Detail Information

Publications41

  1. ncbi Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorates joint swelling in established monkey collagen-induced arthritis
    Yasushi Uchiyama
    Product Research Department, Chugai Pharmaceutical Co, Ltd, Gotemba, Shizuoka, Japan
    Biol Pharm Bull 31:1159-63. 2008
    ..In conclusion, tocilizumab improved established arthritis in monkey and monkey CIA model is useful for the analysis of anti-arthritic effect of tocilizumab...
  2. ncbi Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family
    Masahiko Mihara
    Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co Ltd, 1 135, Komakado, Gotemba, Shizuoka, 412 8513, Japan
    Int Immunopharmacol 5:1731-40. 2005
    ....
  3. ncbi The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody
    Masahiko Mihara
    Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co Ltd, 135, Komakado 1 Chome, Shizuoka, 412 8513 Japan
    Expert Opin Biol Ther 5:683-90. 2005
    ..In all of these diseases, tocilizumab has improved the disease activity, suggesting that IL-6 plays an essential role in the pathogenesis of these diseases...
  4. ncbi Evidence for the role of Th17 cell inhibition in the prevention of autoimmune diseases by anti-interluekin-6 receptor antibody
    Masahiko Mihara
    Product Research Department, Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co Ltd, Komakado 1 Chome, Gotemba shi, Shizuoka, Japan
    Biofactors 35:47-51. 2009
    ..It is thought that this inhibitory action may contribute to the therapeutic effects of anti-IL-6R antibody in human autoimmune diseases...
  5. ncbi Anti-interleukin 6 receptor antibody inhibits murine AA-amyloidosis
    Masahiko Mihara
    Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co Ltd, Shizuoka, Japan
    J Rheumatol 31:1132-8. 2004
    ..We examined whether anti-interleukin 6 receptor (IL-6R) antibody prevented the development of AA-amyloidosis in mouse models...
  6. ncbi Influences of anti-mouse interleukin-6 receptor antibody on immune responses in mice
    Masahiko Mihara
    Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co Ltd, 135, Komakado 1 Chome, Gotemba shi, Shizuoka 412 8513, Japan
    Immunol Lett 84:223-9. 2002
    ..Our results suggest that IL-6 does not always involve antibody production, although IL-6 augments antibody production, and that IL-6 is essential for the induction of Th1 cells...
  7. ncbi IL-6/IL-6 receptor system and its role in physiological and pathological conditions
    Masahiko Mihara
    Fuji Gotemba Research Laboratories, Product Research Department, Chugai Pharmaceutical Co Ltd, Gotemba, Japan
    Clin Sci (Lond) 122:143-59. 2012
    ..In the present review, we first summarize the IL-6/IL-6R system and IL-6 signal transduction, and then go on to discuss the physiological and pathological roles of IL-6...
  8. ncbi Different effects of high molecular weight sodium hyaluronate and NSAID on the progression of the cartilage degeneration in rabbit OA model
    M Mihara
    Product Research Department, Chugai Pharmaceutical Co, Ltd, Shizuoka, Japan
    Osteoarthritis Cartilage 15:543-9. 2007
    ..We examined the effects of nonsteroidal anti-inflammatory drug (NSAID) and intra-articular injections of sodium hyaluronate (HA) on cartilage degeneration in rabbit knee osteoarthritis (OA) model induced by partial meniscectomy...
  9. ncbi IL-6 and IL-1 synergistically enhanced the production of MMPs from synovial cells by up-regulating IL-6 production and IL-1 receptor I expression
    Miho Suzuki
    Product Research Department, Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co, Ltd, Shizuoka, Japan
    Cytokine 51:178-83. 2010
    ....
  10. ncbi Tocilizumab, a humanized anti-interleukin-6 receptor antibody, improved anemia in monkey arthritis by suppressing IL-6-induced hepcidin production
    Misato Hashizume
    Product Research Department, Chugai Pharmaceutical Co, Ltd, 1 135 Komakado, Gotemba, Shizuoka, 412 8513, Japan
    Rheumatol Int 30:917-23. 2010
    ..Blockade of IL-6 signaling rapidly improved anemia in monkey arthritis via the inhibition of IL-6-induced hepcidin production...
  11. ncbi Anti-IL-6 receptor antibody increases blood IL-6 level via the blockade of IL-6 clearance, but not via the induction of IL-6 production
    Yasushi Uchiyama
    Product Research Department, Chugai Pharmaceutical Co Ltd, Japan
    Int Immunopharmacol 8:1595-601. 2008
    ....
  12. ncbi High molecular weight hyaluronic acid relieved joint pain and prevented the progression of cartilage degeneration in a rabbit osteoarthritis model after onset of arthritis
    Misato Hashizume
    Product Research Department, Chugai Pharmaceutical Co Ltd, 1 135 Komakado, Gotemba, Shizuoka 412 8513, Japan
    Mod Rheumatol 20:432-8. 2010
    ..HA also suppressed the production of MMP in joints. Treatment of HA after the onset of cartilage destruction and pain showed a cartilage protective effect as well as an analgesic effect...
  13. ncbi Overproduced interleukin 6 decreases blood lipid levels via upregulation of very-low-density lipoprotein receptor
    Misato Hashizume
    Product Research Department, Chugai Pharmaceutical Co Ltd, 1 135 Komakado, Gotemba, Shizuoka, Japan
    Ann Rheum Dis 69:741-6. 2010
    ..Interleukin 6 (IL6) blockade raises blood lipid levels in patients with rheumatoid arthritis...
  14. ncbi Anemia in monkey collagen-induced arthritis is correlated with serum IL-6, but not TNFalpha
    Yasushi Uchiyama
    Product Research Department, Chugai Pharmaceutical Co Ltd, 1 135, Komakado, Gotemba, Shizuoka, 412 8513, Japan
    Rheumatol Int 28:879-83. 2008
    ..And our data strongly suggest that IL-6 is an essential cytokine for the development of the anemia in monkey CIA...
  15. ncbi Characterization of anti-mouse interleukin-6 receptor antibody
    Makoto Okazaki
    Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co Ltd, 135 Komakado 1 chome, Gotemba shi, Shizuoka 412 8513, Japan
    Immunol Lett 84:231-40. 2002
    ..These lines of evidence demonstrate that MR16-1 is useful to investigate the physiological and pathological roles of IL-6 and sIL-6R in mice...
  16. ncbi Anti-inflammatory mechanism of tocilizumab, a humanized anti-IL-6R antibody: effect on the expression of chemokine and adhesion molecule
    Miho Suzuki
    Product Research Department, Chugai Pharmaceutical Co Ltd, 1 135, Komakado, Gotemba, Shizuoka 412 8513, Japan
    Rheumatol Int 30:309-15. 2010
    ..In conclusion, IL-6 signaling plays an important role in inflammatory cell migration by increasing the rate of cell adhesion and by inducing chemokine production in inflamed joints...
  17. ncbi Anti-IL-6 receptor antibody suppressed T cell activation by inhibiting IL-2 production and inducing regulatory T cells
    Hiroto Yoshida
    Product Research Department, Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co, Ltd, Tokyo, Japan
    Eur J Pharmacol 634:178-83. 2010
    ..Extrapolating these results to the clinical treatment of rheumatoid arthritis, they suggest that IL-6 blockade inhibits T cell activation, whereas TNFalpha blockade does not...
  18. ncbi Combination therapy with eldecalcitol and alendronate has therapeutic advantages over monotherapy by improving bone strength
    Sadaoki Sakai
    Product Research Department, Fuji Gotemba Research Labs, Chugai Pharmaceutical Co, Ltd, Shizuoka, Japan
    Bone 50:1054-63. 2012
    ..In conclusion, the combination therapy of ALN and ED-71 has therapeutic advantages over ALN monotherapy in terms of improving bone mechanical strength without excessive suppression of bone turnover...
  19. ncbi Combination treatment with eldecalcitol (ED-71) and raloxifene improves bone mechanical strength by suppressing bone turnover and increasing bone mineral density in ovariectomized rats
    Satoshi Takeda
    Product Research Department, Chugai Pharmaceutical Co, Ltd, Japan
    Bone 53:167-73. 2013
    ....
  20. ncbi Influence of humanized anti-IL-6R antibody, tocilizumab on the activity of soluble gp130, natural inhibitor of IL-6 signaling
    Misato Hashizume
    Product Research Department, Chugai Pharmaceutical Co Ltd, Gotemba, Shizuoka, Japan
    Rheumatol Int 29:397-401. 2009
    ..In conclusion, tocilizumab exerts its inhibitory effect through the inhibition of IL-6R directly without affecting natural inhibitor sgp130...
  21. ncbi IL-6/sIL-6R trans-signalling, but not TNF-alpha induced angiogenesis in a HUVEC and synovial cell co-culture system
    Misato Hashizume
    Product Research Department, Chugai Pharmaceutical Co, Ltd, Gotemba, Shizuoka 412 8513, Japan
    Rheumatol Int 29:1449-54. 2009
    ..In conclusion, IL-6/sIL-6R complex showed angiogenic activity via the production of VEGF from RA-FLS, but TNF-alpha was anti-angiogenic in our experimental system...
  22. ncbi IL-6 plays an essential role in neutrophilia under inflammation
    Misato Hashizume
    Product Research Department, Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co, Ltd, Japan
    Cytokine 54:92-9. 2011
    ..In conclusion, IL-6 induced neutrophilia and reduced CD162 expression on neutrophils in inflammation...
  23. ncbi Induction of high-dose tolerance to the rat anti-mouse IL-6 receptor antibody in NZB/NZW F1 mice
    Hiroto Yoshida
    Product Research Department, Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co, Ltd, 1 135, Komakado, Gotemba, Shizuoka 412 8513, Japan
    Rheumatol Int 31:1445-9. 2011
    ..It is superior to the anti-CD4 mAb method because it enabled the effects of MR16-1 monotherapy to be evaluated without the confounding effects of anti-CD4 mAb...
  24. ncbi IL-6 blockade preferentially inhibits Th17 differentiation in collagen-induced arthritis
    Hiroto Yoshida
    Product Research Department, Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co, Ltd, 1 135, Komakado, Gotemba, Shizuoka 412 8513, Japan
    Rheumatol Int 31:127-31. 2011
    ..In conclusion, IL-6 inhibition preferentially suppresses the induction of Th17 cells and does not seem to impact on cytokine production of already differentiated Th17 cells...
  25. ncbi Early effects of tocilizumab on bone and bone marrow lesions in a collagen-induced arthritis monkey model
    Atsuhiko Kato
    Safety Assessment Department, Chugai Pharmaceutical Co, Ltd, 1 135 Komakado, Gotemba, Shizuoka 412 8513, Japan
    Exp Mol Pathol 84:262-70. 2008
    ..Tocilizumab treatment recovered changes in the CIA monkeys as a result of the co-differentiation between the osteoclasts and the osteoblast/stramal cells, at least partially through the suppression of RANKL overproduction...
  26. ncbi Interleukin-6 regulates anti-arthritic effect of methotrexate via reduction of SLC19A1 expression in a mouse arthritis model
    Misato Hashizume
    Product Research Department, Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co, Ltd, 1 135 Komakado, Gotemba, Shizuoka, 412 8513, Japan
    Arthritis Res Ther 14:R96. 2012
    ..We found that interleukin-6 (IL-6) regulated the expression of SLC19A1, so we studied the effect of a combination of MTX and anti-mouse IL-6 receptor antibody (MR16-1)...
  27. ncbi Atherogenic effects of TNF-α and IL-6 via up-regulation of scavenger receptors
    Misato Hashizume
    Product Research Department, Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co, Ltd, Gotemba, Japan
    Cytokine 58:424-30. 2012
    ..The present study clearly showed that in patients with chronic inflammation mediated by TNF-α and IL-6, these cytokines are directly implicated in atherosclerotic plaque formation...
  28. ncbi The combination therapy with alfacalcidol and risedronate improves the mechanical property in lumbar spine by affecting the material properties in an ovariectomized rat model of osteoporosis
    Ayako Shiraishi
    Product Research Department, Chugai Pharmaceutical Co, Ltd, 1 135 Komakado, Gotemba, Shizuoka, 412 8513, Japan
    BMC Musculoskelet Disord 10:66. 2009
    ....
  29. ncbi Polyglutamation of a novel antifolate, MX-68, is not necessary for its anti-arthritic effect
    Kazumi Urakawa
    Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co, Ltd, 1 135, Komakado, Gotemba, 412 8513, Shizuoka, Japan
    Eur J Pharmacol 435:237-44. 2002
    ..These results indicate that polyglutamation is not essential for the anti-arthritic effect of antifolates...
  30. ncbi High molecular weight hyaluronic acid inhibits IL-6-induced MMP production from human chondrocytes by up-regulating the ERK inhibitor, MKP-1
    Misato Hashizume
    Product Research Department, Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co, Ltd, 1 135, Komakado, Gotemba, Shizuoka 412 8513, Japan
    Biochem Biophys Res Commun 403:184-9. 2010
    ..Our study is the first to demonstrate that HA suppressed MMPs induction by IL-6 in human chondrocyte via MKP-1 induction through CD44 signaling...
  31. ncbi Blockade of IL-6 and TNF-α inhibited oxLDL-induced production of MCP-1 via scavenger receptor induction
    Misato Hashizume
    Product Research Department, Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co, Ltd, 1 135 Komakado, Gotemba, Shizuoka 412 8513, Japan
    Eur J Pharmacol 689:249-54. 2012
    ..In conclusion, our results strongly support that blocking therapy of IL-6 and TNF-α might be beneficial to reduce atherosclerosis risk in chronic inflammatory diseases...
  32. ncbi Adiponectin induces CCL20 expression synergistically with IL-6 and TNF-α in THP-1 macrophages
    Miho Suzuki
    Product Research Department, Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co, Ltd, Shizuoka, Japan
    Cytokine 58:344-50. 2012
    ..In conclusion, gAd played an important role in CCL20 expression, and MMP-12 induced by IL-6 or TNF-α was involved in the synergistic effect of fAd and cytokines...
  33. ncbi The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis
    Misato Hashizume
    Product Research Department, Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co, Ltd, 1 135 Komakado, Gotemba, Shizuoka 412 8513, Japan
    Arthritis 2011:765624. 2011
    ..In conclusion, IL-6 is a major player in the pathogenesis of RA, and current evidence indicates that the blockade of IL-6 is a beneficial therapy for RA patients...
  34. ncbi Blockade of interleukin-6 signaling aggravates ischemic cerebral damage in mice: possible involvement of Stat3 activation in the protection of neurons
    Toru Yamashita
    Department of Physiology, Keio University School of Medicine, Tokyo, Japan
    J Neurochem 94:459-68. 2005
    ..These results suggest that endogenous IL-6 plays a critical role in preventing damaged neurons from undergoing apoptosis in the acute phase of cerebral ischemia and that its role may be mediated by Stat3 activation...
  35. ncbi IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis
    Satoshi Serada
    Laboratory for Immune Signal, National Institute of Biomedical Innovation, 7 6 8 Saito Asagi, Ibaraki, Osaka 565 0085, Japan
    Proc Natl Acad Sci U S A 105:9041-6. 2008
    ..These findings indicate that anti-IL-6R mAb treatment might represent a novel therapy for human MS...
  36. ncbi [Interleukin-6 in pathogenesis of rheumatoid arthritis]
    Masahiko Mihara
    Fuji-Gotemba Research Laboratories, Chugai Pharmaceutical Co. Ltd
    Nippon Rinsho 63:158-62. 2005
  37. ncbi [MRA for therapy of rheumatoid arthritis]
    Norihiro Nishimoto
    Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University
    Nippon Rinsho 63:538-43. 2005
  38. ncbi Interleukin-6 receptor-mediated activation of signal transducer and activator of transcription-3 (STAT3) promotes choroidal neovascularization
    Kanako Izumi-Nagai
    Department of Ophthalmology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku ku, Tokyo 160 8582, Japan
    Am J Pathol 170:2149-58. 2007
    ....
  39. ncbi Crucial role of the interleukin-6/interleukin-17 cytokine axis in the induction of arthritis by glucose-6-phosphate isomerase
    Keiichi Iwanami
    University of Tsukuba, Tsukuba, Japan
    Arthritis Rheum 58:754-63. 2008
    ..To clarify the glucose-6-phosphate isomerase (GPI)-specific CD4+ T cell lineage involved in GPI-induced arthritis and to investigate their pathologic and regulatory roles in the induction of the disease...
  40. ncbi Mechanism of action of combined short-term CTLA4Ig and anti-CD40 ligand in murine systemic lupus erythematosus
    Xiaobo Wang
    Departments of. Medicine and Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461
    J Immunol 168:2046-53. 2002
    ..These results suggest that the effect of costimulatory blockade in remission induction must be mediated by a different mechanism than is demonstrated in the disease prevention studies...
  41. ncbi A resorcylic acid lactone, 5Z-7-oxozeaenol, prevents inflammation by inhibiting the catalytic activity of TAK1 MAPK kinase kinase
    Jun Ninomiya-Tsuji
    Department of Molecular Biology, Graduate School of Science, Nagoya University, and CREST, Japan Science and Technology Corporation, Chikusa-ku, Nagoya 464-8602, Japan
    J Biol Chem 278:18485-90. 2003
    ..Furthermore, in vivo 5Z-7-oxozeaenol was able to inhibit picryl chloride-induced ear swelling. Thus, 5Z-7-oxozeaenol blocks proinflammatory signaling by selectively inhibiting TAK1 MAPKKK...